Growth Metrics

Opus Genetics (IRD) Retained Earnings (2010 - 2026)

Opus Genetics (IRD) reported Retained Earnings of -$254.1 million for Q1 2026, down 72.65% year-over-year from -$929.1 million in Q1 2025, and down 34.75% on a QoQ basis from -$188.6 million in Q4 2025.

Opus Genetics (IRD) has 17 years of Retained Earnings data on file, last reported at -$254.1 million in Q1 2026.

  • Quarterly Retained Earnings fell 72.65% year-over-year to -$254.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$254.1 million (down 72.65% YoY) and the FY2025 annual result came in at -$188.6 million, down 35.68% from the prior year.
  • Retained Earnings declined to -$254.1 million in Q1 2026 per IRD's latest filing, from -$188.6 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$71.5 million in Q4 2022 and bottomed at -$254.1 million in Q1 2026.
  • The 5-year median for Retained Earnings is -$100.9 million (2022), against an average of -$119.7 million.
  • The widest annual swing landed in 2023, when Retained Earnings increased 27.27%; it then plunged 72.65% in 2026.
  • Tracing IRD's Retained Earnings over 5 years: stood at -$71.5 million in 2022, then dropped by 13.97% to -$81.5 million in 2023, then sank by 70.62% to -$139.0 million in 2024, then sank by 35.68% to -$188.6 million in 2025, then plunged by 34.75% to -$254.1 million in 2026.
  • Per Business Quant, the three latest IRD Retained Earnings figures stand at -$254.1 million (Q1 2026), -$188.6 million (Q4 2025), and -$172.1 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Retained Earnings (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -211.85 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -153.89 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 1.00 Bn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -438.66 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -279.00 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 14.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - 130.89 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 36.42 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -24.89 Mn
10 Opus Genetics 357.99 Mn 298.03 Mn - -254.12 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -254.12 Mn
Dec 31, 2025 -188.59 Mn
Sep 30, 2025 -172.07 Mn
Jun 30, 2025 -154.61 Mn
Mar 31, 2025 -147.19 Mn
Dec 31, 2024 -139.00 Mn
Sep 30, 2024 -103.86 Mn
Jun 30, 2024 -96.34 Mn
Mar 31, 2024 -88.57 Mn
Dec 31, 2023 -81.47 Mn
Sep 30, 2023 -76.67 Mn
Jun 30, 2023 -82.23 Mn
Mar 31, 2023 -77.27 Mn
Dec 31, 2022 -71.48 Mn
Sep 30, 2022 -105.42 Mn
Jun 30, 2022 -100.89 Mn
Mar 31, 2022 -95.96 Mn
Dec 31, 2021 -89.37 Mn
Sep 30, 2021 -83.06 Mn
Jun 30, 2021 -78.83 Mn
Mar 31, 2021 -71.69 Mn
Dec 31, 2020 -32.68 Mn
Sep 30, 2020 -167.82 Mn
Jun 30, 2020 -166.42 Mn
Mar 31, 2020 -163.91 Mn
Dec 31, 2019 -8.06 Mn
Sep 30, 2019 -161.45 Mn
Jun 30, 2019 -159.49 Mn
Mar 31, 2019 -12,602.00
Dec 31, 2018 -154.69 Mn
Sep 30, 2018 -151.57 Mn
Jun 30, 2018 -64,955.00
Mar 31, 2018 -89,376.00
Dec 31, 2017 -140.32 Mn
Sep 30, 2017 -136.73 Mn
Jun 30, 2017 -25,705.00
Mar 31, 2017 -6,326.00
Dec 31, 2016 -6,122.00
Sep 30, 2016 -114.50 Mn
Jun 30, 2016 -111.63 Mn
Mar 31, 2016 -1,406.00
Dec 31, 2015 -105.72 Mn
Sep 30, 2015 -102.86 Mn
Jun 30, 2015 -98.84 Mn
Mar 31, 2015 1,076.00
Dec 31, 2014 -91.33 Mn
Sep 30, 2014 -42,041.00
Jun 30, 2014 -87.22 Mn
Mar 31, 2014 87.41 Mn
Dec 31, 2013 -72.81 Mn
Sep 30, 2013 70.09 Mn
Jun 30, 2013 67.95 Mn
Mar 31, 2013 64.84 Mn
Dec 31, 2012 63.31 Mn
Sep 30, 2012 63.26 Mn
Jun 30, 2012 60.27 Mn
Mar 31, 2012 59.22 Mn
Dec 31, 2011 57.08 Mn
Sep 30, 2011 57.47 Mn
Jun 30, 2011 56.00 Mn
Dec 31, 2010 45.74 Mn